Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2000-07-21
2002-10-22
Nguyen, Dave T. (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S486000, C424S450000, C435S320100, C435S325000, C435S091400, C435S455000
Reexamination Certificate
active
06468986
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.
BACKGROUND OF THE INVENTION
Polycations, such as polylysine, have been used to facilitate delivery of nucleic acids to cell interior. Both in vitro and in vivo applications have taken advantage of this property. See, for example, Gao et al., 1996,
Biochem.
35:1027-1036.
Polynucleotides, typically DNA, may be taken into a cell by a receptor-mediated endocytosis pathway, a cellular mechanism which internalizes specific macromolecules. In general, complexes designed to be delivered in this fashion contain nucleic acids encoding the gene of interest and a polycationic agent, which acts as a DNA-binding carrier and both neutralizes the charge on the nucleic acids and condenses it.
Condensation facilitates entry of nucleic acids into cell vesicle systems by simulating a macromolecular structure. For example, polylysine condenses DNA into a toroid or doughnut-like structure. (Wagner et al., 1991,
Proc. Natl. Acad. Sci.
88:4255-4259).
Polycations previously utilized for nucleic acid delivery to cell interiors include polylysine, protamines, histones, spermine, spermidine, polyornithine, polyargnine, and putrescine.
All publications mentioned herein are incorporated herein by reference for the purpose of disclosing and describing features of the invention for which the publications are cited in connection with.
SUMMARY OF THE INVENTION
An embodiment of the invention is a vector for expression of polypeptides. The vector of the instant invention comprises: (i) an Epstein Barr Virus (EBV) origin of replication; (ii) a polynucleotide encoding an EBV origin binding protein; (iii) an enhancer; (iv) a promoter; and (v) a terminator. Polynucleotides encoding a desired polypeptide, such as erythropoietin or leptin can be inserted into the vector. Also, ribozyme and antisense polynucleotides can also be inserted into the vector.
One embodiment of the invention is a composition capable of targeting a polynucleotide to a specific cell type. The composition comprises: (i) a lipoprotein; (ii) a polynucleotide binding molecule; and (iii) a polynucleotide.
Another embodiment of the invention is a method of increasing the frequency of uptake of polynucleotides into a cell by contacting a cell with a composition comprising: (i) a lipoprotein, (ii) a polynucleotide binding molecule; and (iii) a polynucleotide.
Yet another embodiment of the invention is a method of increasing the frequency of uptake of polynucleotides into a specific cell type by contacting a population of cells with a composition comprising (i) a lipoprotein, (ii) a polynucleotide binding molecule; and (iii) a polynucleotide.
One embodiment of the invention is a polycationic agent exhibiting a net positive electrical charge at physiological pH with the following formula:
where Ta and Tc are terminating groups. A preferred subset of these compounds is the set where R
2
is hydrogen. Even more preferred are polymers comprising at least one unnatural amino acid. Also preferred are polymers where R
2
and R
3
are hydrogen and R
1
is not hydrogen, also referred to as poly N-substituted glycines or “poly NSGs.”
Another embodiment is a neutral polymer exhibiting no net positive or negative electrical charge at physiological pH with the following formula:
where Ta and Tc are terminating groups. A preferred subset of these compounds is the set where R
2
is hydrogen. Even more preferred are polymers comprising at least one unnatural amino acid. Also preferred are polymers where R
2
and R
3
are hydrogen and R
1
is not hydrogen, also referred to as poly N-substituted glycines or “poly NSGs.”
The instant polycationic agents and neutral polymers are capable of neutralizing the electrical charge of nucleic acids. A subset of these compounds are capable of (1) condensing the structure of polynucleotides and/or (2) protecting polynucleotides from serum and/or nuclease degradation.
Yet another embodiment of the invention are polycationic agents and neutral polymers that (1) target binding of nucleic acids to cell surfaces, (2) trigger cell membrane destabilization; (3) exhibit endosome buffering capacity; (4) trigger endocytosis; (5) help trigger the release of polynucleotide/lipid complexes from endosomes or (6) nuclear tropism.
Another embodiment of the invention is a composition comprising a polynucleotide of interest and an effective amount of the polycationic agent to neutralize the charge of the polynucleotide. Optionally, the composition includes a ligand which directs the complex to particular cells expressing a ligand-binding partner, and/or an endosomolytic agent, which serves to cause disruption of the endosome containing the complex.
Another embodiment of the invention is a method of condensing nucleic acids by providing an effective amount of the polycationic agents or neutral polymers of the invention and contacting the agent with the desired polynucleotides.
Also an embodiment of the invention is a method of inhibiting serum and/or nuclease degradation of nucleic acids by providing an effective amount of the polycationic agents or neutral polymers of the inventions and contacting the agent with the desired nucleic acids.
REFERENCES:
patent: 4235886 (1980-11-01), Freidinger et al.
patent: 5041497 (1991-08-01), Bhattacharjee et al.
patent: 5334761 (1994-08-01), Gebeyehu et al.
patent: 5635487 (1997-06-01), Wolf et al.
patent: 5679559 (1997-10-01), Kim et al.
patent: 5780592 (1998-07-01), Mullner et al.
patent: 5925333 (1999-07-01), Krieger et al.
patent: 544292 (1993-06-01), None
patent: 545016 (1993-06-01), None
patent: WO 91/19735 (1991-12-01), None
patent: WO 94/06451 (1994-03-01), None
patent: WO 95/02397 (1995-01-01), None
patent: WO 95/28494 (1995-10-01), None
patent: WO 95/31557 (1995-11-01), None
patent: WO 96/18372 (1996-06-01), None
patent: WO 96/22765 (1996-08-01), None
patent: WO 96/27379 (1996-09-01), None
patent: WO 97/11682 (1997-04-01), None
patent: WO 97/12052 (1997-04-01), None
Raz et al., Cationic Lipids Inhibit Intradermal Genetic Vaccination, 1994, pp. 71-75.*
Anderson et al., Human gene therapy, Apr. 30, 1998, Nature, vol. 392, pp. 25-30.*
Verma et al., Gene therapy-promises, problems and prospects, Sep. 18, 1997, Nature, vol. 389, pp. 239-242.*
Ngo et al., Computational Complexity Protein Structure Prediction, and the Levinthal Parasdox, 1994, vol. 14, pp. 492-495.*
Chiu et al., Optimizing energy potentials for success in protein tertiary sturcture prediction, May 7, 1998, Folding & Design, vol. 3, pp. 223-228.*
Wagner et al., “DNA-Binding Transferrin Conjugates as Functional Gene-Delivery Agents: Synthesis by Linkage of Polylysine or Ethidium Homodimer to the Transferrin Carbohydrate Moiety”Bioconjugate Chem.2(4) :226-231, 1991.
Wagner et al., “Influenza Virus Hemagglutinin HA-2 N-terminal Fusogenic Peptides Augment Gene Transfer by Transferrin-Polylysine-DNA Complexes: Toward a Synthetic Virus-Like Gene-Transfer Vehicle”Proc. Natl. Acad. Sci. USA89:7934-7938, Sep., 1992.
Batra et al., “Receptor-Mediated Gene Delivery Emplyong Lectin-Binding Specificity”Gene Therapy1:255-260, 1994.
Behr et al., “Gene Transfer with Synthetic Cationic Amphiphiles: Prospects for Gene Therapy”Bioconjugate Chem.5:382-389, 1994.
Michael and Curiel, “Strategies to Achieve Targeted Gene Delivery via the Receptor-Mediated Endocytosis Pathway”Gene Therapy1:223-232, 1994.
Gao and Huang, “Potentiation of Cationic Liposome-Mediated Gene Transfer Delivery by Polycations”Biochemistry35:1027-1036, 1996.
Gao and Huang, “Cationic Liposome-Mediated Gene Transfer”Gene Therapy2:710-722, 1995.
Guy et al., “Delivery of DNA into Mammalian Cells by Receptor-Mediated Endocytosis and Gene Therapy”Molecular Biology3:2
Cohen Fred E.
Dubois-Stringfellow Nathalie
Dwarki Varavani
Innis Michael A.
Murphy John E.
Blackburn Robert P.
Chiron Corporation
Gorthey LeeAnn
Nguyen Dave T.
LandOfFree
Compositions and methods for polynucleotide delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for polynucleotide delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for polynucleotide delivery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2999182